Nigeria’s pharmaceutical manufacturing capacity is set for a potential boost with the development of a Pharmaceutical and Biotechnology Industrial Park, known as Pharmacity, in Abuja through a partnership between Bloom Public Health and Centenary City.
The project, being developed through Bloom Pharmacity Limited, is designed to provide an integrated industrial environment for pharmaceutical manufacturers, biotechnology companies and healthcare supply-chain operators seeking to establish or expand production facilities in Nigeria.
The initiative comes amid growing calls for increased domestic pharmaceutical production as Nigeria seeks to reduce its dependence on imported medicines and strengthen healthcare supply-chain resilience. Africa’s pharmaceutical market was valued at approximately $27.65 billion in 2024 and is projected to reach $36.96 billion by 2033, according to Grand View Research.
Nigeria’s pharmaceutical market, estimated at about $3.34 billion in 2026, is projected to grow annually by 9.5 per cent through 2033, according to Coherent Market Insights.
Despite these growth prospects, Nigeria remains substantially dependent on imported medicines and pharmaceutical inputs. The National Agency for Food and Drug Administration and Control (NAFDAC) has identified the expansion of local manufacturing as an important component of the country’s medicine security strategy.
Against this background, Pharmacity is being developed within Centenary City, Abuja, to attract investment into pharmaceutical and biotechnology manufacturing while providing the infrastructure and technical support required to establish production facilities.
The project will occupy several hectares of master-planned industrial land, with serviced plots of approximately 5,000 square metres allocated to prospective manufacturers. Its proposed infrastructure includes internal road networks, power distribution, water supply, effluent and sewage treatment facilities, and gas reticulation.
Bloom Public Health will serve as the technical partner, providing support in Good Manufacturing Practice (GMP) quality management systems, facility layout planning and regulatory-readiness advisory to help participating manufacturers work towards applicable NAFDAC requirements and relevant international standards, including World Health Organisation prequalification requirements where applicable.
The project partners said the model recognises that establishing pharmaceutical manufacturing facilities requires more than acquiring land and installing production equipment, as facility design, production processes, quality assurance, regulatory compliance, utilities, workforce capacity and supply-chain reliability are equally important. By bringing manufacturing facilities and supporting services together within a coordinated industrial zone, Pharmacity aims to improve infrastructure efficiency, reduce duplication of investment and address some of the operational challenges associated with establishing pharmaceutical production facilities.
Speaking on the initiative, Chief Executive Officer of Bloom Public Health, Prof. Chimezie Anyakora, said the project was designed to strengthen Nigeria’s healthcare security through sustainable local manufacturing.
“Nigeria’s healthcare security depends on building sustainable, quality-assured local manufacturing capacity. Pharmacity is designed to move beyond basic industrial real estate by giving pharmaceutical and biotechnology manufacturers an ecosystem where physical infrastructure is directly supported by GMP quality systems and regulatory readiness from the outset,” he said.
The proposed industrial park will incorporate facilities and services to support pharmaceutical manufacturing, including cold-chain and warehousing logistics hubs, quality-control laboratories, regulatory liaison offices and commercial banking services. Its location within Centenary City, close to the Nnamdi Azikiwe International Airport, is expected to provide access to air cargo services and distribution networks across Nigeria and the wider West African market. The project’s position within Centenary City’s Free Zone framework is also expected to offer eligible businesses access to applicable tax, customs and other investment incentives, subject to the necessary approvals and regulatory conditions.
Pharmacity is currently in its primary and secondary infrastructure rollout phase, with the onboarding of initial facilities targeted for the first quarter of 2027. The development is expected to create opportunities for pharmaceutical manufacturers, biotechnology companies, institutional investors, infrastructure providers and specialised healthcare logistics operators. Its success will ultimately depend on its ability to attract credible manufacturers, mobilise investment and support quality-assured production facilities capable of meeting local and international standards.
Bloom Pharmacity Limited has invited pharmaceutical manufacturers, biotechnology companies, infrastructure investors and healthcare logistics operators to engage with its project team. Interested parties can request the project prospectus, obtain information on plot specifications or arrange site visits through the project secretariat.
